期刊
DEPRESSION AND ANXIETY
卷 33, 期 12, 页码 1155-1177出版社
WILEY
DOI: 10.1002/da.22572
关键词
anxiety; anxiety disorders; assessment; diagnosis; epidemiology; international; panic attacks; agoraphobia
资金
- National Institute of Mental Health
- NIMH [R01 MH070884]
- John D. and Catherine T. MacArthur Foundation
- Pfizer Foundation
- US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
- Fogarty International Center [FIRCA R03-TW006481]
- Pan American Health Organization
- Eli Lilly and Company
- Ortho-McNeil Pharmaceutical
- GlaxoSmithKline
- Bristol-Myers Squibb
- State of Sao Paulo Research Foundation (FAPESP) Thematic Project [03/00204-3]
- Ministry of Health
- National Center for Public Health Protection
- Shenzhen Bureau of Health
- Shenzhen Bureau of Science, Technology, and Information
- Ministry of Social Protection
- Center for Excellence on Research in Mental Health (CES University)
- Secretary of Health of Medellin
- European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
- Piedmont Region (Italy)
- Fondo de Investigacion Sanitaria
- Instituto de Salud Carlos III, Spain [FIS 00/0028]
- Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158CE]
- Departament de Salut, Generalitat de Catalunya, Spain
- Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
- United Nations Development Group Iraq Trust Fund (UNDGITF)
- Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU026, H16-KOKORO-013]
- Lebanese Ministry of Public Health
- WHO (Lebanon)
- National Institute of Health/Fogarty International Center [R03 TW006481-01]
- Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences
- AstraZeneca
- Eli Lilly
- Hikma Pharmaceuticals
- Janssen Cilag
- Lundbeck
- Novartis
- Servier
- National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
- National Council on Science and Technology [CONACyT-G30544H]
- Pan American Health Organization (PAHO)
- National Council of Science and Technology [CB-2010-01-155221]
- New Zealand Ministry of Health
- Alcohol Advisory Council
- Health Research Council
- WHO(Geneva)
- WHO (Nigeria)
- Federal Ministry of Health, Abuja, Nigeria
- Health AMP
- Social Care Research AMP
- Development Division of the Public Health Agency
- National Institute of Health of the Ministry of Health of Peru
- Norwegian Financial Mechanism
- European Economic Area Mechanism as well as Polish Ministry of Health
- Champalimaud Foundation
- Gulbenkian Foundation
- Foundation for Science and Technology (FCT)
- Ministry of Public Health (former Ministry of Health)
- US National Institute of Mental Health [R01-MH059575, RO1-MH61905]
- National Institute of Drug Abuse
- South African Department of Health
- University of Michigan
- Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejeria de Sanidad y Politica Social)
- Fundacion para la Formacion e Investigacion Sanitarias (FFIS) of Murcia
- National Institute of Drug Abuse (NIDA)
- Substance Abuse and Mental Health Services Administration (SAMHSA)
- Robert Wood Johnson Foundation [044708]
- John W. Alden Trust
- Medical Research Council of South Africa (MRC)
- VICI [91812607]
- Netherlands Research Foundation (NWO-ZonMW)
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/00204-3] Funding Source: FAPESP
ContextThe scarcity of cross-national reports and the changes in Diagnostic and Statistical Manual version 5 (DSM-5) regarding panic disorder (PD) and panic attacks (PAs) call for new epidemiological data on PD and PAs and its subtypes in the general population. ObjectiveTo present representative data about the cross-national epidemiology of PD and PAs in accordance with DSM-5 definitions. Design and settingNationally representative cross-sectional surveys using the World Health Organization Composite International Diagnostic Interview version 3.0. ParticipantsRespondents (n = 142,949) from 25 high, middle, and lower-middle income countries across the world aged 18 years or older. Main outcome measuresPD and presence of single and recurrent PAs. ResultsLifetime prevalence of PAs was 13.2% (SE 0.1%). Among persons that ever had a PA, the majority had recurrent PAs (66.5%; SE 0.5%), while only 12.8% fulfilled DSM-5 criteria for PD. Recurrent PAs were associated with a subsequent onset of a variety of mental disorders (OR 2.0; 95% CI 1.8-2.2) and their course (OR 1.3; 95% CI 1.2-2.4) whereas single PAs were not (OR 1.1; 95% CI 0.9-1.3 and OR 0.7; 95% CI 0.6-0.8). Cross-national lifetime prevalence estimates were 1.7% (SE 0.0%) for PD with a median age of onset of 32 (IQR 20-47). Some 80.4% of persons with lifetime PD had a lifetime comorbid mental disorder. ConclusionsWe extended previous epidemiological data to a cross-national context. The presence of recurrent PAs in particular is associated with subsequent onset and course of mental disorders beyond agoraphobia and PD, and might serve as a generic risk marker for psychopathology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据